Literature DB >> 8499632

Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state.

J S Ginsberg1, C Demers, P Brill-Edwards, M Johnston, R Bona, R F Burrows, J Weitz, J A Denburg.   

Abstract

The objective of this study is to determine whether patients with systemic lupus erythematosus (SLE) and anticardiolipin antibodies (ACA) have biochemical evidence of an ongoing prothrombotic state. Using a cross-sectional analysis of a cohort design in an outpatient SLE clinic setting, 43 consecutive patients with SLE participated. Patients underwent clinical and laboratory evaluations on two separate occasions at least 3 months apart. As part of the clinical evaluation, the following were ascertained: (1) the ongoing use of warfarin therapy; (2) the presence of prior venous and arterial thromboembolic disease by history, critical review of objective tests, and examination for reflux in the deep veins of the legs as an indicator of venous thrombosis; and (3) disease-related activity by performing a lupus activity criteria count (LACC). As part of the laboratory evaluation, blood was taken on both occasions and assayed for prothrombin fragments (F1 + 2) and fibrinopeptide A (FPA), as indices of thrombin generation and activity, respectively, and ACA. For the analyses, patients were classified as ACA+ if the assay was abnormal on both occasions and ACA- if the assay was negative on both occasions or negative on one occasion and positive on the other. ACA+ patients had: (1) a significantly higher mean level of F1 + 2 (1.07 nmol/L) than ACA- patients (0.79 nmol/L; P = .02) and patients receiving warfarin (0.47 nmol/L; P = .009) and (2) a significantly higher mean level of FPA (1.01 nmol/L) than ACA- patients (0.45 nmol/L; P = .02). When patients with prior thromboembolism were excluded from the analysis, significant differences in the mean levels of F1 + 2 and FPA between ACA+ and ACA- patients were still seen, whereas when patients with prior thromboembolism and/or active disease were excluded from the analysis, a significant difference in the mean level of FPA and a nonsignificant trend in the mean level of F1 + 2 were seen. The results of this study support the hypothesis that the presence of ACA in SLE patients is associated with an ongoing prothrombotic state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499632

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin.

Authors:  Y Sheng; J G Hanly; S W Reddel; S Kouts; J Guerin; T Koike; K Ichikawa; A Sturgess; S A Krilis
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Markers of thrombin and plasmin generation in patients with inherited thrombophilia.

Authors:  L H Lee; I Jennings; R Luddington; T Baglin
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

3.  Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.

Authors:  H Takeya; T Mori; E C Gabazza; K Kuroda; H Deguchi; E Matsuura; K Ichikawa; T Koike; K Suzuki
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

Review 4.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

5.  Thrombin acts as inducer of proinflammatory macrophage migration inhibitory factor in astrocytes following rat spinal cord injury.

Authors:  Ting Yang; Haiyan Jiang; Xinye Luo; Yuxuan Hou; Aicheng Li; Bingqiang He; Xingyuan Zhang; Huifei Hao; Honghua Song; Rixin Cai; Xudong Wang; Yingjie Wang; Chun Yao; Lei Qi; Yongjun Wang
Journal:  J Neuroinflammation       Date:  2022-05-27       Impact factor: 9.587

6.  On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.

Authors:  M D Smirnov; D T Triplett; P C Comp; N L Esmon; C T Esmon
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

7.  A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia.

Authors:  Marcio de Souza Cavalcante; José Camilo Torres-Romero; Marina Duarte Pinto Lobo; Frederico Bruno Mendes Batista Moreno; Leonardo Primo Bezerra; Diego Silva Lima; Jesamar Correia Matos; Renato de Azevedo Moreira; Ana Cristina de Oliveira Monteiro-Moreira
Journal:  Biomark Res       Date:  2016-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.